Generate Biomedicines, Inc.
NASDAQ:GENBAsset Management
+$0.13 today
- Market cap
- $1.34B
- Beta
- 0.19
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$4.06
Volume 1.05M
Average 0.55M
GENB Pre-Tax Margin
Income before tax as a percentage of revenue.
Generate Biomedicines, Inc.NASDAQ: GENB
Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026
Pre-tax margin at -853.9%
Pre-tax margin was -853.9% in Q1 FY2026.
Sources:Income StatementText generated from reported figures; not investment advice.
Pre-Tax Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -698.6%
- Year-over-year change
- +186.9pp
| Period | Period end | Pre-Tax Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -698.6% | +186.9pp |
| FY2024 | 2024-12-31 | -885.5% | — |
Pre-Tax Margin vs competitors
How GENB compares with its peers on the latest reported figures
- GENB's FY2025 pre-tax margin of -698.6% is the 3rd highest of the 5 companies compared; the peer median is -3348.8%.
- Its year-over-year change of +186.9 pp is the 3rd highest of 5, against a peer median of -2001.8 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -154.3% | +211.2 pp | -14.3 pp | |
| LTM Sep 2026 | -251.7% | +328.4 pp | -285.6 pp | |
GENBGenerate Biomedicines, Inc. | FY2025 | -698.6% | +186.9 pp | — |
| LTM Mar 2026 | -6445.8% | -4214.8 pp | -2277.8 pp | |
| LTM Mar 2026 | -10014.1% | -871500.6 pp | -4148.2 pp | |
| Peer median (excluding GENB) | -3348.8% | -2001.8 pp | -1281.7 pp | |
Competitors are the stored peer set for GENB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Revenue | 20.46M | 31.89M |
| Cost of Revenue | 0 | 0 |
| Gross Profit | 20.46M | 31.89M |
| Gross Margin | 100.0% | 100.0% |
| Research & Development | 175.31M | 224.7M |
| Selling, General & Admin | 42.09M | 42.26M |
| Operating Expenses | 217.4M | 266.96M |
| Depreciation & Amortization | 15.35M | 13.18M |
| EBITDA | (163.71M) | (208.49M) |
| EBITDA Margin | -800.2% | -653.7% |
| Operating Income | (196.94M) | (235.07M) |
| Operating Margin | -962.6% | -737.0% |
| Interest Income | 18.12M | 13.66M |
| Interest Expense | 2.12M | 1.14M |
| Other Income / Expenses | 15.77M | 12.26M |
| Income Before Tax | (181.17M) | (222.8M) |
| Pre-Tax Margin | -885.5% | -698.6% |
| Income Tax Expense | 212K | 163K |
| Net Income | (173.77M) | (203.15M) |
| Net Margin | -849.4% | -637.0% |
| EPS (Basic) | (1.68) | (4.98) |
| EPS (Diluted) | (1.68) | (4.98) |
| Weighted Avg Shares | 127.45M | 50.09M |
| Weighted Avg Shares (Diluted) | 127.45M | 50.09M |
Generate Biomedicines, Inc.
NASDAQ:GENB
Intrinsic Alpha fair value
Locked
Current Price
$10.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.